Satellos Bioscience (NASDAQ:MSLE) Stock Rating Upgraded by Canaccord Genuity Group

Posted by Amy Steele on May 23rd, 2026

Satellos Bioscience (NASDAQ:MSLE – Get Free Report) was upgraded by analysts at Canaccord Genuity Group to a “moderate buy” rating in a report issued on Thursday,Zacks.com reports.

A number of other brokerages have also recently issued reports on MSLE. Zacks Research raised Satellos Bioscience to a “hold” rating in a research note on Tuesday, February 10th. Cantor Fitzgerald assumed coverage on shares of Satellos Bioscience in a report on Wednesday, March 11th. They set an “overweight” rating for the company. Leerink Partners assumed coverage on shares of Satellos Bioscience in a report on Monday, April 6th. They set an “outperform” rating and a $20.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Satellos Bioscience in a report on Monday, May 11th. Finally, Wall Street Zen upgraded shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Satellos Bioscience presently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Read Our Latest Stock Report on MSLE

Satellos Bioscience Trading Down 5.5%

MSLE opened at $6.75 on Thursday. The company has a fifty day moving average price of $7.11. Satellos Bioscience has a 52 week low of $4.53 and a 52 week high of $13.39. The company has a market capitalization of $140.60 million, a PE ratio of -4.22 and a beta of 1.60.

Satellos Bioscience (NASDAQ:MSLE – Get Free Report) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). As a group, equities research analysts predict that Satellos Bioscience will post -2.26 EPS for the current year.

Satellos Bioscience Company Profile

(Get Free Report)

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.